Access to the procurement documents is restricted. Further information can be obtained at:
Lot No: 1
II.2.1) Title
Etanercept
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of Etanercept to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per line to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Award criteria
Criteria below:
Quality criterion: Supply chain
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
46 271 726.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
Infliximab IV
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of Infliximab IV to NHS Scotland. The authority intends to award this Lot as a unranked multi-supplier per line to a maximum of five (5) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Award criteria
Criteria below:
Quality criterion: Supply chain
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
18 784 068.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
Infliximab Subcutaneous
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of Infliximab Subcutaneous to NHS Scotland. The authority intends to award this lot as a single supplier framework per line. Full details of Goods and volumes can be found within the ITT documents.
II.2.5) Award criteria
Criteria below:
Quality criterion: Supply chain
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
307 680.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 4
II.2.1) Title
Adalimumab
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of Adalimumab to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per line to a maximum of six (6) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Award criteria
Criteria below:
Quality criterion: Supply chain
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
60 835 914.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 5
II.2.1) Title
Methotrexate (50 mg per 1 ml Concentration) Pre-filled Self Injection Device
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of methotrexate (50 mg per 1 ml concentration) pre-filled self injection device to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per lot to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Award criteria
Criteria below:
Quality criterion: Supply chain
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
18 947 932.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 6
II.2.1) Title
Methotrexate (50 mg per 1 ml Concentration) Pre-filled Syringes
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of Methotrexate (50 mg per 1 ml concentration) pre-filled syringes to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per lot to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Award criteria
Criteria below:
Quality criterion: Supply Chain
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
482 418.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 7
II.2.1) Title
Methotrexate (25 mg per 1 ml Concentration) Pre-filled Self Injection Device
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of methotrexate (25 mg per 1 ml concentration) pre-filled self injection device to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per lot to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Award criteria
Criteria below:
Quality criterion: Supply chain
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
298 263.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 8
II.2.1) Title
Methotrexate (25 mg per 1 ml Concentration) Pre-filled Syringes
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of methotrexate (25 mg per 1 ml concentration) pre-filled syringes to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per lot to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Award criteria
Criteria below:
Quality criterion: Supply chain
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
465 862.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
III.1.3) Technical and professional ability
List and brief description of selection criteria:
(a) Potential framework participants must be able to demonstrate that a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA will be in place for all tendered goods prior to the start date of the framework agreement.
(b) Potential framework participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered goods must comply with the MHRA best practice guidance on labelling and packaging and the National Patient Safety Agency (‘NPSA’) guidelines on packaging and labelling on pack design.
Minimum level(s) of standards required:
(a) Confirmation that a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA will be in place for all tendered goods prior to the start of the framework agreement should be included in the qualification envelope of the ITT under the technical and professional ability: quality control.
(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the qualification envelope of the ITT under the quality assurance schemes.
(c) Confirmation that samples for tendered goods will be supplied upon request to ensure compliance with the MHRA best practice guidance on labelling and packaging and the National Patient Safety Agency (‘NPSA’) guidelines on packaging and labelling on pack design. Confirmation of sample provision should be provided in the qualification envelope of the ITT under technical and professional ability: products.
The estimated values referred to in Section II.I.5) and all lots cover the initial twenty four (24) month duration and the maximum twenty four (24)-month extension period.
The buyer is using PCS-Tender to conduct this ITT exercise. The project code is 17106. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343
The contracting authority does not intend to include a sub-contract clause as part of community benefits (as per Section 25 of the Procurement Reform (Scotland) Act 2014) in this contract for the following reason:
It is not envisaged that sub-contractors will be utilised in delivery of this framework agreement.
The contracting authority does not intend to include any community benefit requirements in this contract for the following reason:
No community benefits will be deliverable through the award of this framework agreement.